Literature DB >> 9613939

Simple high-performance liquid chromatography method for the simultaneous determination of serum caffeine and paraxanthine following rapid sample preparation.

D T Holland1, K A Godfredsen, T Page, J D Connor.   

Abstract

A simple reversed-phase high-performance liquid chromatography (HPLC) method for the simultaneous determination of caffeine and paraxanthine in human serum is described. Serum proteins are precipitated with perchloric acid and the resulting supernatant neutralized for direct injection onto an HPLC column. The method uses a phosphate-methanol mobile phase (85:15, v/v) at pH 4.9 with a flow-rate of 1.75 ml/min and quantitation is by UV absorbance at 274 nm. Elution times are approximately 18 min for caffeine and 8 min for paraxanthine. Theobromine and theophylline have elution times of 5.4 and 9.4 min and do not interfere in the assay. The intra-assay and between-assay means for precision and accuracy for both drugs are: 4.5% C.V. and 3.3% deviation. The sensitivity of the method is 50 ng/ml for each drug.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9613939     DOI: 10.1016/s0378-4347(97)00590-2

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  15 in total

1.  Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.

Authors:  Janne T Backman; Marika T Granfors; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2006-04-27       Impact factor: 2.953

2.  Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.

Authors:  Janne T Backman; Marjo J Karjalainen; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

3.  Combined caffeine and carbohydrate ingestion: effects on nocturnal sleep and exercise performance in athletes.

Authors:  Ben Miller; Helen O'Connor; Rhonda Orr; Patricia Ruell; Hoi Lun Cheng; Chin Moi Chow
Journal:  Eur J Appl Physiol       Date:  2014-08-13       Impact factor: 3.078

4.  In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes.

Authors:  Bill J Gurley; Stephanie F Gardner; Martha A Hubbard; D Keith Williams; W Brooks Gentry; Ikhlas A Khan; Amit Shah
Journal:  Clin Pharmacol Ther       Date:  2005-05       Impact factor: 6.875

5.  Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba.

Authors:  Bill J Gurley; Stephanie F Gardner; Martha A Hubbard; D Keith Williams; W Brooks Gentry; Yanyan Cui; Catharina Y W Ang
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  A comparison of the effects of caffeine following abstinence and normal caffeine use.

Authors:  Merideth A Addicott; Paul J Laurienti
Journal:  Psychopharmacology (Berl)       Date:  2009-09-24       Impact factor: 4.530

7.  Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.

Authors:  Janne T Backman; Marika T Schröder; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2007-10-23       Impact factor: 2.953

8.  Effect of danshen extract on pharmacokinetics of theophylline in healthy volunteers.

Authors:  Furong Qiu; Guangji Wang; Yanan Zhao; Hua Sun; Guoguang Mao; Jiyi A; Jian Sun
Journal:  Br J Clin Pharmacol       Date:  2007-10-24       Impact factor: 4.335

9.  Methodological considerations for the quantification of self-reported caffeine use.

Authors:  Merideth A Addicott; Lucie L Yang; Ann M Peiffer; Paul J Laurienti
Journal:  Psychopharmacology (Berl)       Date:  2008-11-15       Impact factor: 4.530

10.  Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.

Authors:  Marjo J Karjalainen; Pertti J Neuvonen; Janne T Backman
Journal:  Eur J Clin Pharmacol       Date:  2007-07-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.